SynthesisFrontiers in medicine2025
Treating chronic obstructive pulmonary disease with ensifentrine: a systematic review.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extracellular Vesicles as Drivers of Lung Endothelial Dysfunction in ARDS: Mechanisms and Therapeutic Opportunities.Comprehensive Physiology · 2026Review
- Persistently low blood eosinophils identify a high-risk phenotype in COPD.BMC pulmonary medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The cornerstone medications for maintenance of chronic obstructive pulmonary disease (COPD) have remained the same for decades. Despite combination therapy with multiple mechanisms of action, patients with COPD have significant morbidity and frequent exacerbations. New treatments with novel mechanisms of action are needed to decrease exacerbation and improve symptoms. Ensifentrine is a novel dual PDE 3 and 4 inhibitor emerged and established as a promising drug in the treatment and management of COPD. Objectives: The purpose of this study was to examine the pooled efficacy and safety of ensifentrine versus placebo for treatment of moderate to severe COPD. Data sources: We explored PubMed, MEDLINE, and Cochrane Library databases. Study eligibility criteria: Randomized controlled clinical trials (RCTs)comparing ensifentrine 3 mg twice daily to placebo for treating moderate-to-severe COPD were included. Design and method: A systematic review of three RCTs investigating the use of ensifentrine in adults with moderate to severe COPD was performed. Mean and risk differences with 95% confidence intervals (CI) were used to express the pooled effect on continuous and binary outcomes, respectively. Results: This systematic review included data from three randomized controlled trials encompassing a total of 1,715 patients. Of these, 1,057 patients received ensifentrine and 658 received placebo. Ensifentrine was associated with significant improvements in all primary outcomes compared to placebo. The pooled mean differences in peak FEV₁, average FEV₁, and morning trough FEV₁ were 143.91 mL, 91.71 mL, and 43.69 mL, respectively (all Conclusion: Ensifentrine consistently improved pulmonary function tests and symptom scores with a safe adverse effect profile. This systematic review supports the clinical benefits of ensifentrine in patients with moderate to severe COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.